Enrique Poradosu
Founder at NUVECTIS PHARMA, INC.
Net worth: 12 M $ as of 2024-03-30
Profile
Enrique Poradosu is the founder of Nuvectis Pharma, Inc. which is founded in 2020, where he currently holds the title of Executive VP, Chief Scientific & Business Officer.
He held the position of Vice President-Business & Scientific Strategy at Keryx Biopharmaceuticals, Inc. from 2003 to 2016 and Senior VP-Business & Scientific Strategy at Stemline Therapeutics, Inc. from 2016 to 2020.
Dr. Poradosu received his undergraduate and doctorate degrees from The Hebrew University of Jerusalem.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
NUVECTIS PHARMA, INC.
8.46% | 2024-01-02 | 1,503,819 ( 8.46% ) | 12 M $ | 2024-03-30 |
Enrique Poradosu active positions
| Companies | Position | Start |
|---|---|---|
| NUVECTIS PHARMA, INC. | Founder | 2020-07-26 |
Former positions of Enrique Poradosu
| Companies | Position | End |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 2020-11-30 |
| KERYX BIOPHARMACEUTICALS | Chief Tech/Sci/R&D Officer | 2015-12-31 |
Training of Enrique Poradosu
| The Hebrew University of Jerusalem | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
| Nuvectis Pharma, Inc. |
- Stock Market
- Insiders
- Enrique Poradosu
